The Adecco Group 2018 Annual Report
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
2020 Annual Report HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 2
2020 Annual Report HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 2 CONTENTS #TogetherStrong Highlights 3 #TogetherStrong is a tag-name that covers #TogetherStrong aptly describes how we countless initiatives we took to address progressed through and emerged from this Letter to shareholders 7 pressing needs in the dental community extraordinary year. Management commentary 11 in 2020. Straumann Group in brief 12 Strategy in action 17 #TogetherStrong is forward-looking; it Products, solutions and services 21 It started with a website offering scientific expresses purpose, teamwork, courage, Innovation 26 and practical information to help Markets 29 determination, perseverance, moving Business performance (Group) 35 customers and staff through the corona forward and succeeding in turbulent Business performance (Regions) 38 virus crisis. Soon it became a holistic, Business performance (Financials) 44 surroundings – themes that are captured Share performance 46 omni-channel response including a in the pictures and contents of this report. Risk management 49 massive education platform. Sustainability report 57 The #TogetherStrong concept has Corporate governance 80 extended to thousands of activities Compensation report 107 and millions of communications. It demonstrates how the events of 2020 Financial report 123 fuelled our resourcefulness, innovation Appendix 184 and passion for creating opportunities. Global Reporting Initiative (GRI) 185 GRI content -
Longer Term Investments Medical Devices
Longer Term Investments Medical devices Chief Investment Office GWM | 11 April 2019 6:53 pm BST Lachlan Towart, Analyst; Stefan R Meyer, Analyst • The aging population and growth of the over-65 age group will create more opportunities for companies selling medical products and devices. • Other drivers of this industry include better penetration in emerging markets due to improved infrastructure, innovative new treatments, increased affordability due to rising per-capita GDP and a growing prevalence of "lifestyle diseases" such as obesity due to urbanization. • We identified five key markets for implantable or wearable devices, including consumer products such as hearing aids, dental implants and corrective lenses. We estimate their total market size at USD 114.8bn with a rate of potential growth in the mid-single digits. • The theme is relatively defensive and should appeal to quality- focused investors. We recommend exposure to it via a diversified portfolio of stocks across our preferred markets and segments. Medical devices can assist in the treatment of many conditions. Some reduce the risk of a treated condition worsening, perhaps as an alternative to drug therapy; others improve users' quality of life or functionality; and still others can solve problems untreatable with drugs. Devices like joint replacements effectively offer permanent long-term solutions (i.e. a cure). Medical devices are primarily used by the over-65 age group, whose growth will outpace the broader population's over the coming decades. Demand is also supported by the rise of "lifestyle diseases" like obesity, itself related to urbanization. The medical device industry has matured, but still represents a substantial opportunity, in our view. -
312.1.Full.Pdf
Ann Rheum Dis: first published as 10.1136/annrheumdis-2021-eular.1066 on 19 May 2021. Downloaded from 312 Scientific Abstracts Acknowledgements: This study was funded by Novartis Pharma AG. The found many DEGs from baseline with GUS treatment and none with PBO. These authors thank Richard Karpowicz, PhD, of Health Interactions, Inc, for providing included genes related to B-, T-, NK-, and plasma cells (increased by GUS) and medical writing support/editorial support, which was funded by Novartis Pharma- neutrophils, monocytes, eosinophils, and macrophages (decreased by GUS), ceuticals Corporation, East Hanover, NJ, in accordance with Good Publication suggestive of a partial normalization of immune cell composition in whole blood. Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). Conclusion: Using whole transcriptome profiling, we detected DEGs in blood Disclosure of Interests: Gurjit S. Kaeley Consultant of: Novartis Pharmaceuti- samples obtained from PsA pts vs. healthy controls, suggesting a dysregulation cals Corporation, Georg Schett Speakers bureau: AbbVie, Bristol Myers Squibb, of immune cell profiles in PsA. The majority of these disease-associated genes Celgene, Janssen, Eli Lilly, Novartis, and Pfizer, Consultant of: AbbVie, Bristol were modulated by GUS, with directionality toward a normalization of whole Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, and UCB, Grant/research blood transcriptomic signatures. support from: Bristol Myers Squibb, Celgene, GSK, Eli Lilly, and Novartis, Philip REFERENCES: G Conaghan Consultant of: or Speakers bureau: AbbVie, AstraZeneca, Bristol [1] Deodhar A et al. Lancet. 2020;395:1115. Myers Squibb, Eli Lilly, EMD Serono, Flexion Therapeutics, Galapagos, Gilead, [2] Mease P et al. Lancet. 2020;395:1126. Novartis, and Pfizer, Grant/research support from: UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Dennis McGona- Table 1. -
SEB Fund 1 AR 31122019 Final Post BM
Annual Report SEB Fund 1 Status: 31 December 2019 R.C.S K 49 Notice The sole legally binding basis for the purchase of units of the Fund described in this report is the latest valid Sales Prospectus with its terms of contract. Table of Contents Page Additional Information to the Investors in Germany 2 Organisation 3 General Information 5 Management Report 9 Schedule of Investments: SEB Fund 1 - SEB Asset Selection Fund 10 SEB Fund 1 - SEB Europe Index Fund 14 SEB Fund 1 - SEB Global Fund 24 SEB Fund 1 - SEB Global Chance / Risk Fund 33 SEB Fund 1 - SEB Norway Focus Fund 39 SEB Fund 1 - SEB Sustainability Fund Europe 41 SEB Fund 1 - SEB Sustainability Nordic Fund 46 SEB Fund 1 - SEB US All Cap 48 Combined Statement of Operations 50 Combined Statement of Changes in Net Assets 54 Combined Statement of Net Assets 58 Statistical Information 62 Notes to the Financial Statements 74 Audit Report 81 Risk Disclosure (unaudited) 84 Remuneration Disclosure (unaudited) 86 1 Additional Information to the Investors in Germany As at 31 December 2019 Units in circulation: The following Sub-Funds are publicly approved for distribution in Germany: • SEB Fund 1 - SEB Asset Selection Fund • SEB Fund 1 - SEB Global Fund • SEB Fund 1 - SEB Global Chance / Risk Fund • SEB Fund 1 - SEB Sustainability Fund Europe • SEB Fund 1 - SEB Sustainability Nordic Fund The following Sub-Funds are not distributed in Germany: • SEB Fund 1 - SEB Europe Index Fund • SEB Fund 1 - SEB Norway Focus Fund • SEB Fund 1 - SEB US All Cap The information disclosed above is as at 31 December 2019 and this may change after the year end. -
Julius Baer Multicooperation Annual Report 2005 As at June 30, 2005 (Audited)
Julius Baer Multicooperation Annual Report 2005 as at June 30, 2005 (audited) Subscriptions are only valid if made on the basis of the current Prospectus, the latest Annual Report and the latest Semi-Annual Report if published thereafter. The Articles of Association, the valid Prospectus and the Annual and Semi-Annual Reports may be obtained free of charge at the representative in Switzerland and the respective paying agent. Only the German version of the present Annual Report has been reviewed by the independent auditor. Consequently, the independent auditor's report only refers to the German version of the Report; other versions result from a conscientious translation made under the responsibility of the Board. In case of differences between the German version and the translation, the German version shall be the authentic text. AN INVESTMENT FUND DOMICILED IN LUXEMBOURG Representative in Switzerland: Julius Baer Investment Funds Services Ltd., Zurich Paying agent in Switzerland: Bank Julius Bär & Co. AG, Bahnhofstrasse 36, Postfach, CH - 8010 Zurich Paying agent in Germany: Bank Julius Bär (Deutschland) AG, Messe Turm, Friedrich-Ebert-Anlage 49, Postfach 15 01 52, D - 60061 Frankfurt on the Main Paying agent in Austria: Erste Bank der oesterreichischen Sparkassen AG, Graben 21, A - 1010 Vienna Contents Page Organisation and Management 4 Independent Auditor's Report 5 Notes to the Financial Statements 6 Julius Baer Multicooperation (Umbrella Fund) MCOO Julius Baer Multicooperation - Emerging Markets Value Stock Fund HESF Julius Baer Multicooperation -
First-Quarter 2021 Report – Media Release
First-quarter 2021 report – Media Release Straumann Group reports very strong first-quarter sales results accelerated by product launches and consumer focus on oral health . Record quarterly revenue of CHF 470 million, 34% organic growth compared to previous year which was already impacted by the pandemic . Acquisition effect of 2% due to DrSmile . Recent investments and product launches driving growth, performance lifted by strong consumer focus on oral health . Strong organic double-digit growth in all regions; contributions led by the largest regions EMEA and North America . Investment of CHF 170 million by 2029 in China Campus to support future growth . Full-year 2021 outlook raised to organic revenue growth in the mid-to-high twenties percentage range expecting an improvement in profitability (core EBIT margin) compared to 2020 REVENUE BY REGION Q1 2021 Q1 2020 (in CHF million) Europe, Middle East & Africa (EMEA) 214.3 162.2 Change in CHF in % +32.1 0.9 Change in local currencies in % +33.1 7.5 Change organic1 in % +27.0 0.1 % of Group total 45.6 45.4 North America (NAM) 138.0 115.7 Change in CHF in % +19.4 4.9 Change in local currencies in % +27.0 7.9 Change organic1 in % +27.0 7.7 % of Group total 29.4 32.4 Asia Pacific 92.3 53.5 Change in CHF in % +72.4 -25.5 Change in local currencies in % +74.4 -21.7 Change organic1 in % +74.4 -22.1 % of Group total 19.6 15.0 Latin America 25.2 26.0 Change in CHF in % -3.1 -12.0 Change in local currencies in % +23.8 7.3 Change organic1 in % +23.8 7.2 % of Group total 5.4 7.3 GROUP 469.8 357.3 Change in CHF in % +31.5 -4.0 Change in local currencies in % +37.0 1.9 Change organic1 in % +34.0 -1.4 1 Excluding the effects of currencies and acquisitions Page 1/6 Basel, April 29, 2021: The Straumann Group made an exceptional start to 2021 and the solid growth trend experienced in the second half of 2020 accelerated. -
Annual Report 2014
ANNUAL REPORT 2014 Dress €99 Blazer €19.99 H&M SPRING 2015 MODERN ESSENTIALS SELECTED BY DAVID BECKHAM SPRING 2015 Shirt €19.99 H&M SPRING 2014 Sweater € 19.95 — H&M ANNUAL REPORT 2014 — Contents H&M IN WORDS AND PICTURES This is H&M 8 CEO letter 10 2014 in brief 12 Our brands 16 Sustainable development 36 Our employees 42 Expansion 46 History 54 H&M IN FIGURES Administration report, including proposed distribution of earnings 60 Group income statement 66 Consolidated statement of comprehensive income 66 Group balance sheet 67 Group changes in equity 68 Group cash flow statement 69 Parent company income statement 70 Parent company statement of comprehensive income 70 Parent company balance sheet 71 Parent company changes in equity 72 Parent company cash flow statement 73 Notes to the financial statements 74 Signing of the annual report 90 Auditor’s report 91 Corporate governance report, including information about the board of directors 92 Auditor’s statement on the corporate governance report 104 Five year summary 106 The H&M share 107 Financial information and contact details 108 H&M’s annual accounts and consolidated accounts for the financial year 2013/14 comprise pages 60–90. — THIS IS H&M — Fashion and quality at the best price H&M is a leading global fashion company with strong values and a clear business concept. H&M has a passion for fashion, a belief in people and a desire to always exceed customers’ expectations – and to do so in a sustainable way. H&M’s busi- ness concept is to offer fashion and quality at the best price. -
ESG Materiality in the European Equity Market
Università Cattolica del Sacro Cuore Facoltà di Scienze Bancarie, Finanziarie e Assicurative Master of Science in Banking and Finance ESG materiality in the European equity market Student Supervisor Pietro Marchesano Prof. Ettore Croci Università Cattolica del Sacro Cuore Facoltà di Scienze Bancarie, Finanziarie e Assicurative Master of Science in Banking and Finance ESG materiality in the European equity market Student Supervisor Pietro Marchesano Prof. Ettore Croci “Profit for a company is like oxygen for a person. If you do not have enough of it, you are out of the game. But if you think your life is about breathing, you are really missing something”. Peter Drucker Contents Acknowledgements .................................................................................................................................... 5 1. Introduction .......................................................................................................................................... 6 2. Literature Review and motivation ............................................................................................ 12 2.1 A framework to understand responsible finance and ESG analysis ................... 12 2.2 The increasing relevance of ESG screens and sustainable investing .................. 21 2.3 On the convenience of ESG integration .......................................................................... 26 2.4 First evidence on ESG materiality .................................................................................... 34 2.5 Hypotheses -
Business News No
Talacker 41, 8001 Zurich, Switzerland, Phone: +41 43 443 72 00, Fax: +41 43 497 22 70, [email protected], www.amcham.ch, October 2020 / No. 400 Last quarter of a very special year: What is ahead? The latest events (more pictures on pages 4/5) Dear members and friends 2020 started with a boom and had a strongly positive outlook. 20/20 vision is the perfect vision, after all! But as we all know, the year turned out differently. The Swiss-American business relationship had a roaring start. After Q4, 2019, the first quarter of 2020 again saw the US market #1 for Swiss exports, ahead of the German market! Exports to the US grew CHF 974 mio, four times the growth to the EU, while exports to the BRIC countries posted a negative growth of CHF 470 mio. Again, the exports to the USA proved to be the locomotive of the Swiss export industry. As we all know, Q2 Lugano, Annual Dinner, September 17: Franco Polloni Zurich, September 29: J. Erik Fyrwald, saw exports to the US crashing down 22% (EFG Bank / former Ticino Chapter Board Chairman), CEO, Syngenta Group and Board due to the Covid crisis in general and logistics Silvio Napoli (Schindler Holding / Swiss Amcham Member Swiss Amcham [MS] problems as a specific issue. But in the last Chairman), Demis Stucki (EFG Bank / Ticino Chapter months, progress came much faster than Board Chairman) expected and in August, the US market was again the top export market for Switzerland. The Swiss-US Business relationship has everything to flourish in the future. -
ADECCO GROUP AG (Incorporated with Limited Liability in Switzerland) ADECCO INTERNATIONAL FINANCIAL SERVICES B.V
ADECCO GROUP AG (incorporated with limited liability in Switzerland) ADECCO INTERNATIONAL FINANCIAL SERVICES B.V. (incorporated with limited liability in The Netherlands) ADECCO FINANCIAL SERVICES (NORTH AMERICA), LLC (incorporated under the laws of the State of Delaware in the United States of America) EUR 3,500,000,000 Euro Medium Term Note Programme unconditionally and irrevocably guaranteed by ADECCO GROUP AG (incorporated with limited liability in Switzerland) Under this EUR 3,500,000,000 Euro Medium Term Note Programme (the Programme), Adecco Group AG (in its capacity as Issuer, Adecco, and in its capacity as guarantor of Notes issued by AIFS or AFS (each as defined below), the Guarantor), Adecco International Financial Services B.V. (AIFS) and Adecco Financial Services (North America), LLC (AFS and, together with Adecco and AIFS, the Issuers, and each an Issuer) may from time to time issue notes (the Notes) denominated in any currency agreed between the relevant Issuer and the relevant Dealer (as defined below). References in this Base Prospectus to the relevant Issuer shall, in relation to any issue or proposed issue of Notes, be references to whichever of Adecco, AIFS or AFS is specified as the Issuer of such Notes in the applicable final terms document (the Final Terms). The payments of all amounts due in respect of the Notes will be unconditionally and irrevocably guaranteed by the Guarantor (except where Adecco is the Issuer). The maximum aggregate nominal amount of all Notes from time to time outstanding under the Programme will not exceed EUR 3,500,000,000 (or its equivalent in other currencies calculated as described in the Programme Agreement described herein), subject to increase as described herein. -
Around 65% of All Promotions Given in Switzerland Go To
Press release, 28 August 2019 Study available Advance & HSG Gender Intelligence Report 2019 online advance-hsg- Around 65% of all promotions report.ch given in Switzerland go to men Companies with a high degree of gender diversity at every level of seniority are more success- ful. However, companies face challenges when integrating this approach into their strategy and implementing it in practice. Only a few have achieved substantial progress to date. These are the findings of the Advance & HSG Gender Intelligence Report 2019, published today, for which raw data relating to 263,000 employees have been analyzed. Although companies are hiring increas- ing numbers of women, this growing potential is not being used when it comes to promotions. Companies based in Switzerland are hiring increasing numbers of women, at every level. In turn, this builds up a pipeline of highly qualified, highly talented female employees. Women and men also leave their jobs at the same rate, showing that companies’ cultures are becoming more appealing to women looking to develop their careers. However, this growing potential is not being used systematically enough across every level in the corporate hierarchy. While there are equal numbers of men and women in non-managerial positions, the proportion of women in middle-management slumps to 23%, sinking even further to 18% for the top management levels. Women are particularly losing out in terms of internal promotions with around 65% of all promotions going to men. The study believes that the key to achieving greater gender diversity up to the very top of the corporate ladder lies in transparent promotion processes: Unconscious bias should have as little influence as possible. -
Straumann Group 2020 Full-Year Results
#TogetherStrong Virtual2020 full-year townhall results meeting conference Basel, 16 February 2021 1 Disclaimer This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. The Group is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. The availability and indications/claims of the products illustrated and mentioned in this presentation may vary according to country. 2 2 FY 2020, Straumann Group 1 2/15/2021 9:46 PM Agenda Full-year highlights Guillaume Daniellot Business & regional review Peter Hackel Recent achievements & strategy in action Guillaume Daniellot Outlook 2021 Guillaume Daniellot Guillaume Daniellot Q&A and upcoming events Peter Hackel 3 Full-year highlights Guillaume Daniellot, CEO 4 FY 2020, Straumann Group 2 A challenging year with solid results returning to organic growth in the second half of 2020 REVENUE ORGANIC GROWTH1 CORE EBIT MARGIN2 CHF 1.4bn -6% 23.4% -11% vs 2019 +8% organic growth1 in Q4 IFRS EBIT margin: 11% CUSTOMER FOCUS EXPANSION OUTLOOK3 Immediacy DrSmile Further share gains Straumann BLX, Zygoma, TLX Entering into Direct-to-Consumer 2021: high-single-digit percentage marketing with doctor-led treatment organic revenue growth, core EBIT expected to improve vs 2020 1 Organic growth = excluding effects of currencies and business combinations 2 Core figures exclude one-time M&A effects, exceptional 5 pension-plan items, restructuring and non-recurring litigation expenses, amortization and impairment of goodwill and acquisition related intangible assets.